26.08.2023 17:06:58
|
Amgen : Olpasiran Phase 2 Data Shows Continued Reduction Of Lp(a) Nearly A Year After Last Dose
(RTTNews) - Amgen (AMGN) said it presented data from the final analysis of the Phase 2 OCEAN-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.
Results from the OCEAN(a)-DOSE Phase 2 study announced in November of 2022 showed that doses of olpasiran greater than or equal to 75 mg Q12W reduced patients' Lp(a) by more than 95% at week 36. The results from the off-treatment extension period show that patients previously dosed with greater than or equal to 75 mg of olpasiran sustained about 40-50% placebo-adjusted percent reduction in Lp(a) nearly a year after the last dose. No new safety concerns were identified during the off-treatment extension period.
In addition, the study was the first to explore the effects of olpasiran on a key biomarker strongly associated with atherosclerosis, pro-atherogenic OxPL-apoB. During the treatment period, olpasiran showed a dose-dependent reduction in pro-atherogenic OxPL-apoB.
For More Such Health News, visit rttnews.com
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Amgen Inc.mehr Nachrichten
14.02.25 |
Verluste in New York: Dow Jones präsentiert sich am Nachmittag schwächer (finanzen.at) | |
14.02.25 |
Freitagshandel in New York: Dow Jones verliert mittags (finanzen.at) | |
14.02.25 |
Minuszeichen in New York: Dow Jones verliert zum Start des Freitagshandels (finanzen.at) | |
11.02.25 |
Schwache Performance in New York: Dow Jones zum Handelsstart in Rot (finanzen.at) | |
10.02.25 |
Dow Jones 30 Industrial-Titel Amgen-Aktie: So viel hätten Anleger mit einem Investment in Amgen von vor 3 Jahren verdient (finanzen.at) | |
05.02.25 |
Starker Wochentag in New York: Dow Jones schlussendlich freundlich (finanzen.at) | |
05.02.25 |
Börse New York in Grün: NASDAQ 100 zum Ende des Mittwochshandels mit Kursplus (finanzen.at) | |
05.02.25 |
Optimismus in New York: NASDAQ 100 im Plus (finanzen.at) |
Analysen zu Amgen Inc.mehr Analysen
Aktien in diesem Artikel
Amgen Inc. | 279,80 | -1,13% |
|